Similares a GDF2026 - Q&A Discussion Panel Five

20 vecinos (text_768) · 29 views · U.S. Food and Drug Administration · Estados Unidos


★	GDF2026 - Q&A Discussion Panel Five	U.S. Food and Drug Administration @us_fda	29	Estados Unidos
9	GDF2026 - Closing Remarks	U.S. Food and Drug Administration @us_fda	595	Estados Unidos	94
19	GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals	U.S. Food and Drug Administration @us_fda	409	Estados Unidos	93
15	GDF2026 - Quality and Safety Assessment of Extractables/Leachables in Generic Drug Products	U.S. Food and Drug Administration @us_fda	363	Estados Unidos	93
3	GDF2026 - Q&A Discussion Panel Eight	U.S. Food and Drug Administration @us_fda	298	Estados Unidos	97
1	GDF2026 - Q&A Discussion Panel Six	U.S. Food and Drug Administration @us_fda	292	Estados Unidos	98
7	GDF2026 - Q&A Discussion Panel Seven	U.S. Food and Drug Administration @us_fda	203	Estados Unidos	96
5	GDF2026 - Q&A Discussion Panel Four and Day One Closing	U.S. Food and Drug Administration @us_fda	187	Estados Unidos	97
11	GDF2026 - Office of Generic Drugs (OGD) Keynote	U.S. Food and Drug Administration @us_fda	144	Estados Unidos	93
2	GDF2026 - Q&A Discussion Panel Two	U.S. Food and Drug Administration @us_fda	136	Estados Unidos	97
8	GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote	U.S. Food and Drug Administration @us_fda	101	Estados Unidos	95
12	GDF2026 - Pre-Abbreviated New Drug Application (ANDA) Meetings for Complex Drug Products	U.S. Food and Drug Administration @us_fda	101	Estados Unidos	93
10	GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides	U.S. Food and Drug Administration @us_fda	86	Estados Unidos	94
4	GDF2026 - Q&A Discussion Panel Three	U.S. Food and Drug Administration @us_fda	72	Estados Unidos	97
17	GDF2026 - FDA Commissioner Keynote	U.S. Food and Drug Administration @us_fda	66	Estados Unidos	93
20	GDF2026 - Drug-Device Combination Products: A Quality Perspective	U.S. Food and Drug Administration @us_fda	64	Estados Unidos	93
18	GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions	U.S. Food and Drug Administration @us_fda	58	Estados Unidos	93
14	GDF2026 - Prioritization Requests: Prioritizing Original and Supplemental ANDAs	U.S. Food and Drug Administration @us_fda	49	Estados Unidos	93
13	GDF2026 - Factors that Can Facilitate Assessment of Type II Drug Master Files (DMFs)	U.S. Food and Drug Administration @us_fda	43	Estados Unidos	93
16	GDF2026 - Orange Book: How Drug Product Listings are Added, Updated, and Maintained	U.S. Food and Drug Administration @us_fda	39	Estados Unidos	93
6	GDF2026 - Q&A Discussion Panel One	U.S. Food and Drug Administration @us_fda	19	Estados Unidos	96